Tagrisso for glioblastoma?

Short answer: No. Tagrisso (osimertinib) is not approved for glioblastoma. It is approved for certain EGFR-mutant non–small cell lung cancer and, in theory, could have CNS activity because it crosses the blood–brain barrier. But there is no established evidence that it improves outcomes in glioblastoma, and it is not a standard treatment outside of clinical trials.

What this means in practice:
- Some early-phase trials have explored osimertinib for glioblastoma with EGFR alterations (like EGFR amplification or EGFRvIII), but results have been limited and it’s not part of standard care yet.
- If you’re considering this, it would be in the context of a clinical trial or specialized discussion with a neuro-oncology team.
- Conventional treatment for glioblastoma (surgery, radiotherapy, temozolomide) remains the standard of care.

If you want, I can help you:
- Find ongoing clinical trials evaluating osimertinib in glioblastoma and summarize their eligibility criteria.
- Review the patient’s tumor molecular profile (e.g., EGFR amplification/EGFRvIII) to assess potential trial relevance.
- Discuss typical side effects and drug interactions to bring to a clinician.

Would you like me to look up current trials or summarize any trial results you’ve seen?